SCHEMBL14948925

SCHEMBL14948925

CC(C)(C)OC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccc(Cl)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.54
TAS1R1 Q7RTX1 1/20 0.54
MAPT P10636 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM4E B2RXH2 1/20 0.51
MAPK1 P28482 1/20 0.51
OPRK1 P41145 1/20 0.48
KLK5 Q9Y337 1/20 0.48
POLB P06746 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
FPR2 P25090 1/20 0.47
MMP1 P03956 1/20 0.47
MMP3 P08254 1/20 0.47
MMP9 P14780 1/20 0.47
CTSL P07711 2/20 0.47
ITGA4 P13612 1/20 0.46
ITGB7 P26010 1/20 0.46
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7339833 0.86 REN (0.49) MAPTNPSR1POLBTDP1CTSL
SCHEMBL7339827 0.86 REN (0.49) MAPTNPSR1POLBTDP1CTSL
SCHEMBL14952573 0.84 FPR2 (0.65) TAS1R3TAS1R1MEN1KMT2AFPR2
SCHEMBL14937926 0.84 FPR2 (0.65) TAS1R3TAS1R1MEN1KMT2AFPR2
SCHEMBL5421613 0.80 MAPT (0.60) MAPTNPSR1MEN1KMT2AKDM4E
SCHEMBL14948969 0.80 TP53 (0.52) MAPTNPSR1MEN1KMT2AKLK5
SCHEMBL5421619 0.80 MAPT (0.60) MAPTNPSR1MEN1KMT2AKDM4E
SCHEMBL14948981 0.79 FPR2 (0.50) MAPTMEN1KMT2AKLK5POLB
SCHEMBL14948943 0.79 FPR2 (0.50) MAPTMEN1KMT2AKLK5POLB
SCHEMBL14948944 0.79 MEN1 (0.50) MAPTNPSR1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3088385-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2016-11-02 EP disclosed
US-8816076-B2 Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2014-08-26 US disclosed
US-8541577-B2 Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2013-09-24 US disclosed
US-20130123496-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 US disclosed
WO-2013070600-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123496-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR3, FPR2 TAS1R3 352/4885TAS1R1 196/4885MAPT 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.